Wrote this analysis in Sept. 2018:

"Despite a rich valuation at about 13 times FY18 sales, Teladoc could prove to be a healthy investment for investors with a decade-long horizon."

$TDOC is up +127% since then. The market? Flat.

$CVS $UNH $SPY

https://t.co/psEvOO155z